Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Sort descending Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Alecensaro Alectinib Locally advanced or metastatic ALK+ NSCLC (first line) Reimburse with clinical criteria and/or conditions Complete
Alecensaro Alectinib Anaplastic Lymphoma Kinase-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Reimburse with clinical criteria and/or conditions Complete
Alecensaro alectinib ALK-positive NSCLC Pending
Alecensaro Alectinib Non-Small Cell Lung Cancer Do not reimburse Complete
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete
Amevive Alefacept Psoriasis, moderate to severe chronic plaque Do not list Complete
Lemtrada Alemtuzumab Multiple sclerosis, relapsing-remitting Withdrawn
Lemtrada Alemtuzumab Multiple sclerosis, relapsing-remitting List with criteria/condition Complete
Fosavance 70/5600 Alendronate sodium / cholecalciferol Osteoporosis List in a similar manner to other drugs in class Complete
Fosavance Alendronate sodium/cholecalciferol Osteoporosis Do not list Complete